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Abstract
Background: Cancer patients receiving radiotherapy often experience fatigue and impaired quality of life (QOL).
Many side effects of radiotherapy are believed to be associated with increased oxidative stress and inflammation
due to the generation of reactive oxygen species during radiotherapy. Hydrogen can be administered as a
therapeutic medical gas, has antioxidant properties, and reduces inflammation in tissues. This study examined
whether hydrogen treatment, in the form of hydrogen-supplemented water, improved QOL in patients receiving
radiotherapy.
Methods: A randomized, placebo-controlled study was performed to evaluate the effects of drinking hydrogen-
rich water on 49 patients receiving radiotherapy for malignant liver tumors. Hydrogen-rich water was produced by
placing a metallic magnesium stick into drinking water (final hydrogen concentration; 0.55~0.65 mM). The Korean
version of the European Organization for Research and Treatment of Cancer’s QLQ-C30 instrument was used to
evaluate global health status and QOL. The concentration of derivatives of reactive oxidative metabolites and
biological antioxidant power in the peripheral blood were assessed.
Results: The consumption of hydrogen-rich water for 6 weeks reduced reactive oxygen metabolites in the blood
and maintained blood oxidation potential. QOL scores during radiotherapy were significantly improved in patients
treated with hydrogen-rich water compared to patients receiving placebo water. There was no difference in tumor
response to radiotherapy between the two groups.
Conclusions: Daily consumption of hydrogen-rich water is a potentially novel, therapeutic strategy for improving
QOL after radiation exposure. Consumption of hydrogen-rich water reduces the biological reaction to radiation-
induced oxidative stress without compromising anti-tumor effects.
Background
Radiotherapy is one of the major treatment options for
malignant neoplasms. Nearly half of all newly diagnosed
cancer patients will receive radiotherapy at some point
during treatment and up to 25% may receive radiother-
apy a second time [1]. While radiotherapy destroys
malignant cells, it adversely affects the surrounding nor-
mal cells [2]. Acute radiation-associated side effects
include fatigue, nausea, diarrhea, dry mouth, loss of
appetite, hair loss, sore skin, and depression. Radiation
increases the long-term risk of cancer, central nervous
system disorders, cardiovascular disease, and cataracts.
The likelihood of radiation-induced complications is
related to the volume of the irradiated organ, the radia-
tion dose delivered, the fractionation of the delivered
dose, the delivery of radiation modifiers, and individual
radiosensitivity [3]. Most radiation-induced symptoms
are believed to be associated with increased oxidative
stress and inflammation, due to the generation of reac-
tive oxygen species (ROS) during radiotherapy, and may
significantly affect the patient’s quality of life (QOL) [2].* Correspondence: anakao@imap.pitt.edu4Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh,
Pennsylvania, USA
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Hydrogen, a therapeutic medical gas, has antioxidant
properties and reduces inflammatory events in tissues
[4-6]. Drinking liquids supplemented with hydrogen
represents a novel method of hydrogen gas delivery that
is easily translatable into clinical practice, with beneficial
effects for several medical conditions, including athero-
sclerosis, type 2 diabetes, metabolic syndrome, and cog-
nitive impairment during aging and in Parkinson’s
disease [7-11]. Currently, there is no definitive therapy
to improve the QOL of patients receiving radiotherapy.
Drinking solubilized hydrogen on a daily basis may be
beneficial and would be quite easy to administer without
complicating or changing a patient’s lifestyle. We
hypothesized that oral intake of hydrogen-rich water,
generated via a magnesium stick, would reduce adverse
events in patients receiving radiotherapy.
Methods
Subjects and design
The study was a two-arm, randomized, controlled clini-
cal trial. Patients were randomly assigned to receive
either hydrogen-rich water or placebo water on the first
day of radiation treatment, and received follow-up ques-
tionnaires on compliance and potential adverse effects.
Eligible patients were informed of the study during
scheduling of pre-radiation testing. Patient characteris-
tics, including tumor origin and the specifics of radio-
therapy, are listed in Table 1. Forty-nine subjects (33
men and 16 women) were enrolled between April and
October 2006. The age of the patients ranged from 21
to 82 years (mean age 58.6 years). All patients were
diagnosed either histologically or pathologically with
hepatocellular carcinoma (HCC) or metastatic hepatic
tumors. All participants received 5040-6500 cGy of
radiotherapy for 7-8 weeks using a 6 MV system (Cyber
Knife, Fanuc, Yamanashi, Japan). The planned target
volume of the initial field was assessed by a localization/
simulation procedure or by computed tomography
(CT)-assisted planning and encompassed the primary
tumors and a 2 cm margin. Blocks were used to shield
normal tissue.
Hydrogen-rich water was produced by placing a
metallic magnesium stick (Doctor SUISOSUI®, Frien-
dear, Tokyo, Japan) into drinking water (Mg + 2H2O ®
Mg (OH)2 + H2; final hydrogen concentration:
0.55~0.65 mM). The magnesium stick contained 99.9%
pure metallic magnesium and natural stones in a poly-
propylene and ceramic container. The subjects were
randomly assigned to groups to either drink hydrogen-
rich water for 6 weeks (n = 25) or drink water contain-
ing a placebo (a casing-only stick placed in drinking
water) (n = 24). Subjects were provided with four 500
mL bottles of drinking water per day and instructed to
place two magnesium sticks in each bottle of water at
the end of each day in preparation for consumption the
following day. Participants were asked to drink 200-300
mL from one bottle each morning, and 100-200 mL
every a few hours from the remaining three bottles. Sub-
jects were instructed to reuse the magnesium sticks by
transferring the sticks to a new bottle of water after use.
The subjects were expected to consume 100-300 mL of
hydrogen-rich water more than 10 times per day for a
total minimum consumption of 1500 mL (1.5 L) and a
maximum consumption of 2000 mL (2.0 L). Oral intake
of hydrogen water or placebo water started on the first
day of radiotherapy and continued for 6 weeks. All the
patients survived through the 6 week follow-up period
when the QOL questionnaire was administered. This
study was conducted in accordance with Good Clinical
Practice guidelines and the ethical principles of the
Declaration of Helsinki (2000). The study protocol and
materials were approved by the Institutional Review
Board of Catholic University Medical College, and all
subjects provided written informed consent prior to
participation.
QOL Assessment
The Korean version of the European Organization for
Research and Treatment of Cancer’s QLQ-C30 instru-
ment with modifications was used to evaluate global
health status and create QOL scales [12]. The descrip-
tive, mailed survey developed by our institute was used
in this study. The questionnaire contains five functional
scales (physical, cognitive, emotional, social, and role-
functioning), three symptom scales (pain, fatigue, and
nausea/vomiting), and six single items to assess addi-
tional symptoms (dyspnea, insomnia, loss of appetite,
constipation, diarrhea). For all items, a response scale
ranging from 0-5 was used. A higher score reflected a
higher level of symptoms and decreased QOL. Assess-
ments were performed before radiotherapy and every
week for 6 weeks after the initiation of radiotherapy.
Biomarker analysis
The concentrations of derivatives of reactive oxidative
metabolites (dROMs) and biological antioxidant power
(BAP) in the peripheral blood were assessed using a free
Radical Analytical System (FRAS4; H&D, Parma, Italy)
on the first day of radiation therapy (week 0) and after 6
weeks of radiotherapy. Blood samples were obtained
from all patients after overnight fasting. FRAS4 dROMs
kits were used to measure total hydroperoxide levels,
which are representative of the total dROMs produced
as a result of peroxidation chain reactions of proteins,
lipids, and amino acids. Results were expressed in U.
CARR; 1 U.CARR is equivalent to 0.08 mg/dl of hydro-
gen peroxide and the value is directly proportional to
the concentration, according to Lambert-Beer’s law.
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Table 1 Patient Characteristics
water Age gender times diagnosis isodose
curve
(%)
total
cGy
volume
(cc)
collimater
(cc)
response water age gender times diagnosis isodose
curve
(%)
total
cGy
volume
(cc)
collimater
(cc)
response
1 placebo 76 M 3
3
HCC 80
75
3,900
3,900
2.521
2.746
7.5
7.5
NR HW 52 M 3 liver meta
of colon
ca
74 3,600 12.283 15 NR
2 placebo 82 M 1 HCC 70 1,200 11.769 20 CR HW 56 M 3 liver meta
of colon
ca
85 3,600 2.552 12.5 PR
3 placebo 57 F 3 bile duct
ca
80 3,000 40.334 30 PR HW 77 F 3 liver meta
of colon
ca
75 3,000 107.136 20 CR
4 placebo 47 F 9 liver meta.
of sarcoma
80
82
84
3,600
3,600
3,900
10.628
6.542
2.673
25
20
15
NR HW 57 M 3 HCC 70 3,600 47.679 15 NR
5 placebo 50 F 3 liver meta
of colon
ca
80 3,900 16.237 20 NR HW 66 M 3 HCC 80 3,600 16.216 25 PR
6 placebo 21 F 3 liver meta.
of ovarian
ca
85 3,600 29.398 30 CR HW 57 M 3 HCC 80 3,600 35.303 30 NR
7 placebo 65 M 3 liver meta.
of rectal
ca
70 3,000 182.871 40 PR HW 47 M 3 HCC 77 3,000 17.65 20 CR
8 placebo 73 M 3 liver meta.
of rectal
ca
75 3,600 37.937 20 PR HW 49 M 3 HCC 80 3,300 53.578 12.5 PR
9 placebo 58 M 3 liver meta.
of
pancreatic
ca
75 3,000 65.637 35 CR HW 71 F 3 HCC 85 3,000 3.861 10 NR
10 placebo 64 M 3 HCC 70 3,000 140.136 20 PR HW 45 M 3 HCC 80 3,600 28.286 15 NR
11 placebo 65 F 3 HCC 70 3,600 48.645 25 PR HW 45 F 3 liver meta.
of gastric
ca
85 3,000 38.938 15 PR
12 placebo 80 M 3 HCC 80 3,000 209.954 25 NR HW 56 F 3 Adrenal
metastasis
of HCC
80 3,600 9.494 15 PR
13 placebo 56 M 3 HCC 85 3,600 15.365 15 CR HW 49 M 3 Adrenal
metastasis
of HCC
75 3,000 91.223 20 NR
14 placebo 61 F 3 HCC 70 3,000 98.957 30 NR HW 60 M 3 LN
metastasis
of HCC
75 3,000 120.366 25 NR
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Table 1 Patient Characteristics (Continued)
15 placebo 46 M 3 HCC 80 3,000 20.848 25 CR HW 47 M 3 LN
metastasis
of HCC
80 3,000 80.459 25 NR
16 placebo 70 F 3 HCC 85 3,600 16.908 20 PR HW 50 M 3 HCC 75 3,600 29.422 20 NR
17 placebo 44 M 3 HCC 85 3,600 16.612 30 NR HW 49 F 3 HCC 70 3,000 156.289 40 PR
18 placebo 48 M 3 HCC 85 3,000 35.093 20 NR HW 63 F 3 HCC 75 3,900 5.425 20 NR
19 placebo 76 F 3 HCC 85 3,600 5.75 15 NR HW 51 M 3 HCC 70 4,000 28.637 35 NR
20 placebo 60 M 3 HCC 83 3,600 6.802 12.5 NR HW 67 F 3 HCC 80 3,600 20.122 20 PR
21 placebo 77 M 3 HCC 75 3,300 33.282 25 PR HW 56 M 3 HCC 70 3,600 23.5 20 CR
22 placebo 55 M 3 HCC 83 3,600 11.963 20 NR HW 78 F 3 HCC 83 3,600 26.456 25 NR
23 placebo 57 M 3 HCC 70 3,000 75.782 40 NR HW 56 M 3 HCC 77 3,600 31.908 20 CR
24 placebo 65 M 2 HCC 75 3,000 55.191 25 NR HW 60 M 3 HCC 70 3,600 36.479 30 PR
HW 70 M 3 HCC 76 3,600 63.434 40 NR
M: male, F: female, HCC: hepatocellular carcinoma, NR: no response, PR: partial response, CR: complete response, HW: hydrogen water.
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Redox potential, including glutathione peroxidase and
superoxide dismutase, were determined using the
FRAS4 BAP test [13]. Described briefly, the samples to
be tested were dissolved in a colored solution containing
a source of ferric ions and a chromogenic substance (a
sulfur-derived compound). After a 5-minute incubation
period, the degree of discoloration and intensity of the
change were directly proportional to the ability of the
plasma to reduce ferric ions. The amount of reduced
ferric ions was calculated using a photometer to assess
the intensity of discoloration; BAP results were
expressed as µmol/l of reduced Fe/l.
Blood chemistry tests for aspartate aminotransferase,
alanine aminotransferase, gamma-glutamyl transpepti-
dase (g-GTP), and total cholesterol, as well as blood
hematology tests for red blood cell count, white blood
cell count, and platelet count were conducted at week 0
and week 6 using standard assays in an accredited hos-
pital laboratory.
Assessment of response
Patients underwent dynamic CT scans 1-2 months after
completion of radiation treatment and tumor response
was checked at 2-3 month intervals thereafter. Treat-
ment response and local recurrence were evaluated
using follow-up dynamic CT scans and serum tests for
alpha-fetoprotein (AFP) and prothrombin, which is
induced by vitamin K absence or antagonist-II (PIVKA-
II). Tumor response was determined by the criteria
established by Kwon et al. [14]. Described briefly, com-
plete response (CR) was defined as the disappearance of
any intratumoral arterial enhancement in all target
lesions. Partial response (PR) was defined as at least a
30% decrease in the sum of the diameters of viable tar-
get lesions. Progressive disease (PD) was defined as an
at least 20% increase in the sum of the diameters of
viable target lesions or the appearance of a new lesion.
Stable disease (SD) was defined as a tumor status that
did not meet any of the above criteria.
Statistical analysis
Unpaired t tests were used to compare numerical data
and the Yates 2 x 2 chi-square test or Fisher exact prob-
ability test was used to compare categorical data. Statis-
tical analyses were performed using SAS 6.13 software
(SAS Institute Inc., Cary, NC). The sample size of 49
patients was sufficient to detect a change in mean scores
of RORTC QLQ-C30.
Results
Hydrogen water improved the QOL of patients receiving
radiotherapy
The QOL of the patients who were given placebo water
deteriorated significantly within the first month of
radiotherapy (Figure 1A). There were no differences
between the groups in the QOL subscales for fatigue,
depression, or sleep. Gastrointestinal (GI) symptoms are
one of the most common complaints of patients under-
going radiotherapy and are considered to have a high
impact on the patient’s QOL after 6 weeks of radiother-
apy. The patients consuming hydrogen water experi-
enced significantly less appetite loss and fewer tasting
disorders compared to the patients consuming placebo
water. No significant difference was seen in the mean
scores for vomiting or diarrhea (Figure 1B).
Hydrogen water mitigated oxidative stress marker during
radiotherapy
Before treatment, there were no differences in total hydro-
peroxide levels, representative of total dROM levels,
between the treatment groups. Radiotherapy markedly
increased total hydroperoxide levels in the patients con-
suming placebo water. However, drinking hydrogen water
prevented this increase in total serum hydroperoxide, as
determined by the dROM test (Figure 2A), indicating
decreased oxidative stress during radiotherapy in the
vomiting appetite loss
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Figure 1 Placebo water and hydrogen water improved the
QOL of patients receiving radiotherapy. A. Weekly assessment of
the patients’ QOL. B. Scoring system of GI symptoms after 6 weeks
of radiotherapy with or without hydrogen water.
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patients who consumed hydrogen water. Similarly, endo-
genous serum antioxidant activity significantly deterio-
rated during radiotherapy in the patients consuming
placebo water, and biologic antioxidant activity was main-
tained in patients who consumed hydrogen-rich water,
even after 6 weeks of radiotherapy (Figure 2B).
Hydrogen water did not compromise the radiation
treatment efficacies
Tumor response to radiotherapy was similar between
the treatment groups, and 12 of 24 (50.0%) patients in
the placebo group and 12 of 25 (48%) patients in hydro-
gen water group exhibited either a completed response
(CR) or a partial response (PR). There were no patients
in either group with progressive disease (PD) during the
follow-up period (3 months). Thus, drinking hydrogen
water did not compromise the anti-tumor effects of
radiotherapy.
Hydrogen treatment did not alter liver function or blood
composition during radiotherapy
There were no significant differences in aspartate ami-
notransferase, alanine aminotransferase, gamma-gluta-
myl transpeptidase (g-GTP) and total cholesterol levels
at week 0 and week 6, regardless of the type of water
consumed (Table 2), indicating that hydrogen water
consumption did not alter liver function. Similarly, there
were no significant differences in red blood cell count,
white blood cell count, or platelet count between
patients consuming hydrogen water and patients con-
suming placebo water (Table 3).
Discussion
To our knowledge, this is the first report demonstrating
the benefits of drinking hydrogen water in patients
receiving radiation therapy for malignant tumors. This
finding may provide the foundation for a clinically
applicable, effective, and safe strategy for the delivery of
hydrogen gas to mitigate radiation-induced cellular
injury. Patients experience GI symptoms and decreased
QOL during radiotherapy. These symptoms usually
occur as a result of the body repairing damage to
healthy cells, are particularly common towards the end
of a course of radiation treatment, and can last for some
time. The symptoms and their impact on QOL can be
worsened by having to travel to the hospital each day.
Drinking hydrogen-rich water improved the QOL of the
patients receiving radiotherapy and did not require addi-
tional hospital visits. Although overall survival of
patients with malignant tumors should remain oncolo-
gists’ primary concern, survival should also be inter-
preted in light of symptom palliation and overall QOL,
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Figure 2 Hydrogen water mitigated oxidative stress marker
during radiotherapy. Antioxidative effects in patients with placebo
water (n = 24) and hydrogen rich water (n = 25). The dROM level
(A) represents the total level of peroxide metabolities, and BAP (B)
reflects serum antioxidant capacity.
Table 2 Changes in liver function tests
Placebo Hydrogen water
all (n = 25) male (n = 17) female (n = 8) all (n = 25) male (n = 16) female (n = 9)
AST(IU/L)
Week 0 24.8 ± 9.1 25.6 ± 5.7 23.1 ± 10.4 25.3 ± 6.7 25.9 ± 5.3 23.9 ± 8.3
Week 6 26.3 ± 6.7 26.9 ± 7.1 25.4 ± 6.8 26.8 ± 8.2 27.2 ± 9.9 26.4 ± 5.1
ALT(IU/L)
Week 0 27.4 ± 15 28.1 ± 11 26.5 ± 17 26.9 ± 8.7 27.1 ± 6.7 26.7 ± 10.3
Week 6 28.8 ± 14 28.7 ± 16 27.6 ± 12 28.1 ± 6.5 28.8 ± 7.3 27.6 ± 9.9
g-GPT(IU/L)
Week 0 61.9 ± 54.3 62.3 ± 35.6 60.5 ± 64.7 62.3 ± 26.2 62.1 ± 34.8 62.4 ± 47.9
Week 6 62.8 ± 22.8 63.2 ± 16.5 62.7 ± 25.9 63.6 ± 36.2 63.9 ± 54.2 63.2 ± 27.4
AST(IU/L)
Week 0 24.8 ± 9.1 25.6 ± 5.7 23.1 ± 10.4 25.3 ± 6.7 25.9 ± 5.3 23.9 ± 8.3
Week 6 26.3 ± 6.7 26.9 ± 7.1 25.4 ± 6.8 26.8 ± 8.2 27.2 ± 9.9 26.4 ± 5.1
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because the side effects of radiotherapy may negate the
putative benefit of improved survival. Oral intake of
daily hydrogen-supplemented water might be a prophy-
lactic strategy to improve QOL of the patients receiving
radiotherapy.
Although the mechanisms underlying the beneficial
effects of hydrogen-rich water during radiotherapy have
not been clearly elucidated, drinking hydrogen-supple-
mented water reduced dROM levels and maintained
BAP levels in the serum, suggesting hydrogen-rich water
exhibits potent systemic antioxidant activity. Previous
experimental studies have linked daily consumption of
hydrogen-rich water with improvement of a number of
conditions in rodent models, including reducing athero-
sclerosis in apolipoprotein E knockout mice [10], alle-
viating cisplatin-induced nephrotoxicity [15], reducing
vitamin C deficiency-induced brain injury [16], prevent-
ing chronic allograft nephropathy after renal transplan-
tation [17], and ameliorating cognitive defects in
senescence-accelerated mice [9] and a Parkinson’s dis-
ease model [7]. In human studies, consumption of
hydrogen-rich water prevented adult-onset diabetes and
insulin resistance [11], as well as oxidative stress in
potential metabolic syndrome [8].
Radiotherapy is associated with an increase in ROS, fol-
lowed by damage to DNA, lipids, and proteins, and acti-
vation of transcription factors and signal transduction
pathways. It has been estimated that 60-70% of the ioniz-
ing radiation-induced cellular damage is caused by
hydroxyl radicals [18]. Therefore, a number of trials with
the goal of reducing adverse effects due to excess ROS
production have been performed with antioxidants deliv-
ered during the course of radiotherapy. Supplementation
with a-tocopherol improves the salivary flow rate and
maintains salivary parameters [19]. Treatment with the
antioxidant enzyme superoxide dismutase prevented
radiotherapy-induced cystitis and rectitis in bladder can-
cer patients receiving radiotherapy [20]. In addition, the
combined use of pentoxifylline and vitamin E reduced
radiation-induced lung fibrosis in patients with lung
cancer receiving radiotherapy [21]. Thus, in general, sup-
plementation with antioxidants is likely to offer overall
benefits in the treatment of adverse effects of radiother-
apy. However, not all antioxidants can afford radiopro-
tection [22-24]. Furthermore, of significant concern is
the finding that high doses of antioxidants administered
as adjuvant therapy might compromise the efficacy of
radiation treatment and increase of the risk of local
recurrence of cancer [25,26]. Hence, the relatively lower
toxicity associated with the use of these antioxidant
agents is appealing, but not at the cost of poor tumor
control. In contrast, in this study, drinking hydrogen-rich
water did not affect radiotherapy’s anti-tumor effects.
Our results may suggest that hydrogen water functions
not only as an antioxidant, but also plays a protective
role by inducing radioprotective hormones or enzymes.
Although further studies are warranted to elucidate the
safety of hydrogen-rich water and determine the optimal
concentration of hydrogen in drinking water, as well as
involved mechanisms, daily intake of hydrogen-rich
water may be a promising approach for counteracting
radiation-induced impairments to QOL. This therapeutic
use of hydrogen is also supported by the work of Qian et
al., who demonstrated that treating human lymphocyte
AHH-1 cells with hydrogen before irradiation signifi-
cantly inhibited ionizing irradiation-induced apoptosis
and increased cell viability in vitro. They also showed
that injection of hydrogen-rich saline could protect the
gastrointestinal endothelia from radiation-induced injury,
decrease plasma malondialdehyde and intestinal 8-hydro-
xydeoxyguanosine levels, and increase plasma endogen-
ous antioxidants in vivo [27].
Conclusions
In conclusion, our study demonstrated that drinking
hydrogen-rich water improved QOL and reduced oxida-
tive markers in patients receiving radiotherapy for liver
tumors. This novel approach of oral intake of hydrogen-
rich water may be applicable to a wide range of radia-
tion-related adverse symptoms.
Table 3 Peripheral blood cell counts
Placebo Hydrogen water
all (n = 25) male (n = 17) female (n = 8) all (n = 25) male (n = 16) female (n = 9)
The number of leukocytes (× 102 /μL)
Week 0 55.8 ± 15.6 58.5 ± 12.7 52.8 ± 16.4 56.2 ± 16.7 57.3 ± 17.2 55.4 ± 15.1
Week 6 53.9 ± 21.4 54.1 ± 22.7 53.7 ± 19.8 54.7 ± 28.7 55.1 ± 31.2 53.8 ± 19.4
The number of erythrocytes (× 104 /μL)
Week 0 474.2 ± 38.3 492.3 ± 45.8 460.8 ± 30.5 482.5 ± 42.1 496.6 ± 50.7 472.9 ± 36.4
Week 6 462.1 ± 52.4 473.8 ± 42.1 456.4 ± 62.2 479.5 ± 36.5 486.4 ± 29.4 470.7 ± 40.5
The number of thrombocytes (×104 /μL)
Week 0 25.7 ± 6.5 26.4 ± 4.7 24.7 ± 5.9 26.4 ± 7.1 26.9 ± 5.5 26.1 ± 4.8
Week 6 24.5 ± 4.7 25.9 ± 2.8 23.4 ± 6.4 25.7 ± 4.8 26.1 ± 4.7 25.3 ± 3.9
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